ESTA Stock Forecast & Price Target

Establishment Labs Holdings Inc. is positioned for significant growth with management projecting annual revenue increases of over 20% from 2026 to 2028, driven by market expansion and the introduction of new products such as Mia and Preservé. The anticipated stronger than expected sales of Motiva implants in the U.S. and improved international growth further enhance the company's financial outlook. Additionally, the expectation of becoming cash flow positive by 2026, alongside improved margins, provides a solid foundation for sustained financial performance.

Establishment Labs Holdings Inc. faces a negative outlook primarily due to anticipated revenue growth declining to less than 20%, impacted by lower-than-expected sales of its Motiva implants in the U.S. market and a slower path to profitability. Additionally, the company is exposed to significant risks including disappointing sales performance in the U.S., potential economic downturns affecting international revenue, and adverse real-world complication rates that could further harm their market position. Lastly, the possibility of a dilutive equity offering adds another layer of uncertainty, potentially impacting shareholder value.